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ABSTRACT Receptor-mediated changes in cAMP production play an essential role in sympathetic and parasympathetic
regulation of the electrical, mechanical, and metabolic activity of cardiac myocytes. However, responses to receptor activation
cannot be easily ascribed to a uniform increase or decrease in cAMP activity throughout the entire cell. In this study, we used a
computational approach to test the hypothesis that in cardiac ventricular myocytes the effects of b1-adrenergic receptor (b1AR)
and M2 muscarinic receptor (M2R) activation involve compartmentation of cAMP. A model consisting of two submembrane
(caveolar and extracaveolar) microdomains and one bulk cytosolic domain was created using published information on the
location of b1ARs and M2Rs, as well as the location of stimulatory (Gs) and inhibitory (Gi) G-proteins, adenylyl cyclase isoforms
inhibited (AC5/6) and stimulated (AC4/7) by Gi, and multiple phosphodiesterase isoforms (PDE2, PDE3, and PDE4). Results
obtained with the model indicate that: 1), bulk basal cAMP can be high (;1 mM) and only modestly stimulated by b1AR
activation (;2 mM), but caveolar cAMP varies in a range more appropriate for regulation of protein kinase A (;100 nM to ;2
mM); 2), M2R activation strongly reduces the b1AR-induced increases in caveolar cAMP, with less effect on bulk cAMP; and 3),
during weak b1AR stimulation, M2R activation not only reduces caveolar cAMP, but also produces a rebound increase in
caveolar cAMP following termination of M2R activity. We conclude that compartmentation of cAMP can provide a quantitative
explanation for several aspects of cardiac signaling.
INTRODUCTION
It is well accepted that receptor-mediated changes in cAMP
production play an essential role in autonomic regulation of
cardiac function. b1-adrenergic receptors (b1ARs) increase
cAMP production through stimulatory G-protein (Gs)-
dependent activation of adenylyl cyclase (AC), and M2 mus-
carinic receptors (M2Rs) antagonize b1AR responses through
inhibitory G-protein (Gi)-dependent inhibition of AC activ-
ity. M2Rs also produce a delayed stimulatory response that
involves an increase in cAMP production (1).
Despite the large number of studies demonstrating an es-
sential role for cAMP inmediating autonomic responses in the
heart, several observations remain incompletely understood.
For example, it has been estimated that the cellular concen-
tration of cAMP in cardiac preparations is ;1 mM under
unstimulated conditions (2,3). Furthermore, cAMP produces
most of its acute functional responses through the activation
of protein kinase A (PKA). However, the regulatory subunits
of PKA bind cAMP with an afﬁnity of 100–300 nM (4,5).
This suggests that PKA is almost fully activated under resting
conditions. If this is true, then how can bAR stimulation of
cAMP production elicit responses that are known to involve
activation of PKA?One possible explanation, which has been
around for over 30 years, is that the changes in cAMP re-
sponsible for generating functional responses occur in a
microdomain that is somehow isolated from the bulk of the
cell (6). Support for this hypothesis comes from studies
demonstrating that changes in the relative amount of cAMP
and PKA activity in the membrane or particulate fraction of
cardiac preparations correlates more closely with the regula-
tion of functional responses than changes in cAMP activity
observed in the soluble or cytosolic fractions (7–9).
There are also unanswered questions concerning the mech-
anisms by which changes in cAMP are involved in musca-
rinic responses. For instance, it has not always been possible
to demonstrate that muscarinic antagonism of b-adrenergic
responses corresponds with a decrease in the total cAMP
content of cardiac preparations (10). Furthermore, M2R ac-
tivation can produce cAMP-dependent stimulatory responses
in addition to the inhibitory effects. What’s more, the stim-
ulatory effects exhibit much slower kinetics (11–13). So how
can M2R activation produce both inhibition and stimulation
of cAMP-dependent effects, and why are there differences in
the kinetics of the two types of responses? At least part of the
answer lies in the fact that cardiac myocytes express multiple
isoforms of AC. These include AC5 and AC6 as well as AC4
and AC7 (14,15). Yet, not all AC isoforms respond to Gi
activation in the same manner. The activated a-subunit of Gi
(Gia) directly inhibits AC5/6, but not AC4/7 (16–18). In
fact, AC4/7 is actually stimulated by free bg-subunits
released upon activation of Gi (19,20).
The opposing effects of Gi activation on different types of
AC activity can explain the inhibitory and stimulatory effects
that M2R activation has on cAMP-dependent responses in
ventricular myocytes (11). However, it doesn’t explain the dis-
parity in the kinetics of the responses. Again, compartmentation
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of cAMP production may be involved. Evidence in sup-
port of this idea comes from studies demonstrating how dif-
ferent components of the signaling pathways are organized
in the membrane. For example, AC5/6 is consistently
associated with caveolar domains of the plasma membrane,
whereas AC4/7 activity is associated with extracaveolar do-
mains (21). This indicates that muscarinic inhibition and stim-
ulation of cAMP occur in different subcellular locations. This
has led us to hypothesize that compartmentation of cAMP
can explain the complex temporal response produced by M2R
activation.
In this study, we used a computational approach to de-
termine whether or not compartmentation of cAMP may be
important in answering the above questions. However, ear-
lier models of cAMP signaling in the heart did not consider
compartmentation or muscarinic modulation of b-adrenergic
responses (22,23). Therefore, we developed a new theoret-
ical framework that incorporates existing information on the
subcellular location of the various elements involved in
cAMP production and degradation as well as the kinetics of
critical reactions in both b1AR and M2R signaling pathways.
The resulting model was then used to predict the effects that
receptor activation has on cAMP concentrations in caveolar,
extracaveolar, and bulk cytoplasmic compartments. The
results demonstrate that basal concentrations of cAMP in the
caveolar compartment can be maintained at a level signif-
icantly lower than that of the total cell so that b1AR activa-
tion may then regulate the activity of PKA through changes
in the concentration of cAMP in this microdomain. The re-
sults also demonstrate that even when there are only minimal
changes in total cellular cAMP levels, M2R stimulation can
signiﬁcantly inhibit cAMP levels in the caveolar domain.
Finally, the model demonstrates that the delayed stimulatory
response to M2R activation is consistent with limited diffu-
sion of cAMP from an extracaveolar domain to the caveolar
domain, where PKA activity is regulated.
METHODS
Strategy for model design
Our goal was to determine whether a compartmental model can quantita-
tively explain the changes in cAMP in cardiac ventricular myocytes in
response to activation of adrenergic and muscarinic receptors. We designed
the model to be realistic, in the sense of being consistent with available
information on the molecules involved. In particular, the model includes
multiple isoforms of AC and phosphodiesterase (PDE), which have been
proposed to be critical for regulation of cAMP levels. For these reasons, the
model includes many molecular entities, each of which requires several
parameters to deﬁne its functional behavior. Some of the parameters are
strongly constrained by existing experimental data, but others are not (as
discussed further below). We manually varied the parameters, within the
range consistent with existing data, to best describe experimental results on
cAMP levels in basal and stimulated conditions. From a mathematical
perspective, the model is underdetermined, in that there are more available
parameters than are likely to be strictly necessary to produce any single
desired output. Consequentially, the parameter set presented here is highly
unlikely to be unique. Because our goal was not to provide quantitative
estimates for any particular model parameters, we have not performed a
formal sensitivity analysis, but we note in the Discussion some of the values
that strongly affected key features of the model output. In essence, we
present this model as a ‘‘proof of concept’’, to demonstrate that a mole-
cularly realistic compartmental model can account for regulation of cAMP
levels under a variety of experimental conditions. We expect that this model
will also provide a basis for interpreting future studies on molecular per-
turbations of the system (e.g., inhibition of a particular PDE isoform).
Cell size and composition
A mathematical model of b1-adrenergic and M2 muscarinic receptor regu-
lation of cAMP production in a cardiac ventricular myocyte was developed
for this study. As in previous theoretical studies (24), the myocyte is as-
sumed to be a cylinder with the following characteristics: length ¼ 100 mm,
radius¼ 10mm, surface area¼ 6.93 104 mm2, and volume¼ 383 106 ml.
Existing kinetic data on the signaling pathways involved in regulating
cAMP production and degradation were incorporated into a model consist-
ing of three different compartments (Fig. 1). The ﬁrst is the subsarcolemmal
space reﬂecting the caveolar domains of the cell. The key signaling elements
included in that compartment have been found in cholesterol-rich membrane
fractions that are associated with caveolin 3, the muscle speciﬁc form of
FIGURE 1 Compartmentation of cAMP signaling path-
ways in a cardiac ventricular myocyte. b1-adrenergic
receptor (b1); M2 muscarinic receptor (M2); stimulatory
(Gs) and inhibitory G-proteins (Gi); adenylyl cyclase type 5
or 6 (AC5/6) and 4 or 7 (AC4/7); phosphodiesterase type 2
(PDE2), 3 (PDE3), and 4 (PDE4); cAMP ﬂux between
caveolar and extracaveolar (JCav/Ecav), extracaveolar and
bulk cytosolic (JEcav/Cyt), and caveolar and bulk cytosolic
(JCav/Cyt) compartments.
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caveolin that is involved in creating signaling complexes necessary for
producing functional responses (25–27). Major signaling components
placed in the caveolar domain are b1ARs, M2Rs, Gs, Gi, AC5/6, as well
as phosphodiesterase types 2 (PDE2), 3 (PDE3), and 4 (PDE4). The size of
this compartment is ;1% of the cytosolic volume, and it encompasses 10%
of the plasma membrane surface area (28).
The second compartment reﬂects the subsarcolemmal space associated
with cholesterol-rich lipid rafts that do not include caveolin. In the model,
this extracaveolar domain contains b1ARs, M2Rs, Gi, Gs, AC4/7, as well as
PDE2 and PDE4. The size of this compartment is ;2% of the cytosolic
volume, and it encompasses 20% of the plasma membrane. The ﬁnal domain
is the bulk cytoplasmic compartment, which makes up ;50% of the total
cell volume (28,29) and is associated with plasma membrane that contains
many of the components described above, but to a lesser degree.
The signaling elements included in the model are listed in Table 1. They
were placed in speciﬁc domains based on studies using biochemical methods
to detect the presence of protein in different cell or membrane fractions. Due
to limited quantitative information, elements that have been reported to exist
in more than one domain were assumed to be distributed uniformly between
relevant compartments. In some instances, functional studies were used as
evidence that a particular signaling element is not uniformly distributed (see
below).
Most numerical values used for the parameters found in the model are
either taken directly from a single experimental source or constrained by a
range deﬁned by multiple experimental sources (see Appendix I). However,
no published quantitative data was available for the rate constants for Gi
activation, the amount of each PDE isoform found in different subcellular
compartments, or the cAMP ﬂux rates.
To convert the amount of a speciﬁc protein described as a fraction of total
membrane protein to the amount of that protein in a single ventricular
myocyte, it is assumed that 1 mg of total membrane protein ¼ 7.5 3 105
myocytes (30).
Computational components
Ligand/receptor/G-protein modules
The ternary complex model was used to describe the interaction between
ligand, receptor, and G-protein (31). Brieﬂy, the model characterizes the
ability of the agonist to promote and stabilize the formation of a high afﬁnity
active ternary complex (LRG), starting from a low afﬁnity binary ligand-
receptor (LR) complex and G-protein (G). Due to the speed of these reac-
tions (when compared to the other reactions present in the model), they are
assumed to be at quasiequilibrium and are represented by algebraic equa-
tions. The same formalism was used to describe both b1-adrenergic receptor
and M2 muscarinic activation in all relevant compartments.
Module input:
Ligand concentration (constant during a simulation).
Free G-protein concentration (Gabg ¼ Gfree).
Module output:
Receptor bound G-protein concentration (RG 1 LRG).
Isoproterenol/b1 adrenergic receptor/Gs module
Rb1Total ¼ Rb1free1 LIsoRb11 LIsoRb1Gs1Rb1Gs
LIsoRb1 ¼ ðLIso3Rb1freeÞ=KL
LIsoRb1Gs ¼ ðLIso3Rb1free3GsfreeÞ=ðKH=KL3KCÞ
Rb1Gs ¼ ðRb1free3GsfreeÞ=KC:
Acetylcholine/M2 muscarinic receptor/Gi module
RM2Total ¼ RM2free1 LAchRM21 LAchRM2Gi1RM2Gi
LAchRM2 ¼ ðLAch3RM2freeÞ=KL
LAchRM2Gi ¼ ðLAch3RM2free3GifreeÞ=ðKH=KL3KCÞ
RM2Gi ¼ ðRM2free3GifreeÞ=KC:
G-protein activation module
The ratio between the total number of Gi and Gs molecules in cardiac cells is
;2:1 (30,32,33). Experimental evidence suggests that there is approxi-
mately equal distribution of Gs between caveolar and noncaveolar mem-
brane domains, whereas Gi is almost entirely present in the caveolar domain
(34). The activation kinetics of Gs were derived from published data (35) and
modiﬁed to obtain subsecond kinetics for G-protein activation, in agreement
with previous studies (36). Although the absolute rate constants for Gi ac-
tivation have not been determined, the rate of Gi activation has been reported
to be slower than that of Gs. Based on this information, it was assumed that
the Gi activation rate is 50% of that determined for Gs.
Module input:
Receptor bound G-protein concentration (RG 1 LRG).
Module output:
G-protein subunits concentration (Ga-GTP, Ga-GDP, Gbg).
Free G-protein concentration (Gabg ¼ Gfree).
The following formulations are applicable both to Gs and Gi and their
corresponding receptors (b1AR and M2R).
dðGa-GTPÞ=dt ¼ RG3 kact21 LRG3 kact1  GGTP3 khydr
dðGbgÞ=dt ¼ RG3 kact21 LRG3 kact1  GGDP3Gbg3 kreas
dðGaGDPÞ=dt ¼ GGTP3 khydr  GGDP3Gbg3 kreas
GTotal ¼ Gabg1Ga-GTP1Ga-GDP:
The output of the combined LRG and G-protein activation modules was
validated by comparing the simulated concentration-response curve for iso-
proterenol stimulation of Gsa accumulation (not shown) with published ex-
perimental data (37).
Adenylyl cyclase modules
Adenylyl cyclase activities were divided into two functionally distinct cate-
gories:AC5/6 andAC4/7. Both categories are stimulated byGs activation, but
with very different afﬁnities. The EC50 for Gsa stimulation of AC4/7 is;32
nM, whereas for AC5/6 it is;200 nM (38,39). This signiﬁcantly affects the
sensitivity of each AC category to b1AR stimulation. Each category of AC
activity is also affected differently byGi activation.AC5/6 is inhibited byGia,
whereas AC4/7 is not. Furthermore, AC4/7 is stimulated synergistically by
Gibg in the presence of Gsa activation (39). As described below, parameter
values were obtained by using a Hill equation to ﬁt the experimentally
determined relationship between G-protein subunits and AC activity.
TABLE 1 Subcellular distribution of cAMP signaling elements
Cav Ecav Cyt References
b1AR X X (54,34,69,7)
M2R X X (54,34,7)
Gs X X (54,34,69,7,70)
Gi X X (54,34,7,70)
AC5/6 X (54,69,7,71,27)
AC4/7 X X (71,27,7)
PDE2 X X X (72,73,65,74)
PDE3 X X (75,72,4,76,73,65,74)
PDE4 X X X (77,72,4,73,65,74)
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Adenylyl cyclase 5/6 module. The activity of AC5/6 and its regulation
by Gs and Gi were simulated using a formulation to describe data obtained
from isolated membrane preparations (37,40). This activity was then scaled
up using an ampliﬁcation factor (AF5/6) that was deﬁned by the ratio of the
activity produced by equal amounts (1 mg) of puriﬁed and membrane
protein in the presence of a maximally stimulating concentration of Gsa.
Module input:
Gsa and Gia concentration (Gsa-GTP, Gia-GTP).
Module output:
cAMP produced by AC5/6.
kAC5=6 ¼ 0:71 3:82343GsaGTP
0:9787
0:19861GsaGTP
0:9787
 
3 11
1
1:4432
3
 1:00613Gia 0:8356
0:19181Gia
0:8356
 
3
MWAC5=6
60
3 10 3
dðcAMPAC5=6Þ
dt
¼ ðkAC5=63AC5=63AF5=6Þ3ATP
KmATP1ATP
:
Adenylyl cyclase 4/7 module. AC4/7 activity and its regulation by Gs
and Gi were simulated using a formulation based on published experimen-
tal data (41,39,42). Because of their structural and functional similarities
(43), the kinetic properties of AC2 were used to describe the behavior of
AC4/7, where necessary. The total amount of AC4/7 present in the cell was
assumed to be ;10% of AC5/6 (44,45). An ampliﬁcation factor (AF4/7) was
calculated as it was for AC5/6.
Module input:
Gsa and Gia concentration (Gsa-GTP, Gibg).
Module output:
cAMP produced by AC4/7.
kAC4=7-Ecav ¼ 0:0631 2:013ðGsaGTP3 10
3Þ1:0043
31:5441 ðGsaGTP3 103Þ1:0043
 
3 11
1
3:01
3
49:13 ðGibg3 103Þ0:8921
25:441 ðGibg3 103Þ0:8921
 
3
MWAC4=7
60
3 10 3
dðcAMPAC4=7-EcavÞ
dt
¼ ðkAC4=7-Ecav3AC4=7-Ecav3AF4=7Þ3ATP
KmATP1ATP
kAC4=7-Cyt ¼ 1:083103
dðcAMPAC4=7-CytÞ
dt
¼ ðkAC4=7-Cyt3AC4=7-Cyt3AF4=7Þ3ATP
KmATP1ATP
:
Phosphodiesterase modules
The total cellular protein content of the various PDE isoforms found in
cardiac myocytes has been reported. However, the only information avail-
able on the subcellular location of the different PDE isoforms describes
their presence in membrane (particulate) and/or cytosolic (soluble) frac-
tions. How the membrane associated PDE activity is distributed between
caveolar and extracaveolar domains is not known. The available descrip-
tive information, along with functional studies, was used as a guide in
determining the relative ratio of each PDE isoform to be included in the
various compartments.
Module input:
cAMP concentration for the speciﬁc compartment.
Module output:
cAMP degraded by PDEs.
The general formulation used for each PDE isoform (PDEx) is:
dðcAMPPDExÞ
dt
¼ ðkPDEx3PDExÞ3cAMP
KmPDEx1cAMP
:
cAMP ﬂux modules
Initial rates for ﬂux of cAMP between compartments were based on pre-
viously published estimates (46).
Module input:
cAMP concentration.
Module output:
cAMP concentration.
dðcAMPCavÞ
dt
¼ dðcAMPAC5=6Þ
dt
 dðcAMPPDE2Þ
dt
1
dðcAMPPDE3Þ
dt
1
dðcAMPPDE4Þ
dt
 
 JCav=Ecav3 cAMPCav  cAMPEcav
VCav
 
 JCav=Cyt3 cAMPCav  cAMPCyt
VCav
 
dðcAMPEcavÞ
dt
¼ dðcAMPAC4=7-EcavÞ
dt
 dðcAMPPDE2Þ
dt
1
dðcAMPPDE4Þ
dt
 
1 JCav=Ecav3
cAMPCav  cAMPEcav
VEcav
 
 JEcav=Cyt3 cAMPEcav  cAMPCyt
VEcav
 
dðcAMPCytÞ
dt
¼ dðcAMPAC4=7-CytÞ
dt
 dðcAMPPDE2Þ
dt
1
dðcAMPPDE3Þ
dt
1
dðcAMPPDE4Þ
dt
 
1 JCav=Cyt3
cAMPCav  cAMPCyt
VCyt
 
1 JEcav=Cyt3
cAMPEcav  cAMPCyt
VCyt
 
:
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Implementation and validation
The model was implemented in Java (J2SE). Differential equations were
solved using an iterative Euler approach. Predictions made by the model are
compared to two types of previously published data. The ﬁrst are cAMP
measurements obtained using biochemical methods to determine the cAMP
content of homogenized tissue or whole cell lysates. These data are assumed
to reﬂect what is happening to cAMP at the level of the whole cell. The
second are measurements of changes in cAMP activity in intact ventricular
myocytes using a FRET-based biosensor (47). This probe consists of two
separate proteins: the catalytic subunit of protein kinase A (PKA) labeled
with yellow ﬂuorescent protein (Cat-YFP) and the type II regulatory subunit
labeled with cyan ﬂuorescent protein (RII-CFP). FRET occurs when PKA is
in the inactive state, and Cat-YFP and RII-CFP are bound to one another. An
increase in cAMP causes molecular rearrangement of the subunits, which
results in a decrease in FRET. By convention the FRET response is deﬁned
as the change in CFP/YFP ﬂuorescence ratio relative to the baseline ratio
(DR/Ro), so that an increase in cAMP results in an increasing ‘‘FRET
response’’, even though there is actually a decrease in FRET. These data are
assumed to reﬂect what is happening to cAMP activity in the caveolar
domain, where cAMP levels are expected to correlate most directly with
functional responses regulated by type II PKA.
RESULTS
Basal cAMP levels
We ﬁrst validated the model’s prediction of cAMP levels
under basal conditions. In the absence of any agonist, pre-
vious studies have suggested that the basal concentration of
cAMP in cardiac myocytes is;1 mM (2,3). However, this is
well above the cAMP afﬁnity of PKA (#300 nM), which is
the primary effector for this cyclic nucleotide (4,5). This
apparent discrepancy may be due to cAMP measurements
having been made using traditional biochemical methods
involving homogenized tissue or whole cell lysates, which
represent what is happening on average throughout the
whole cell, but may not accurately reﬂect what is happening
in discrete microdomains where PKA-mediated functional
responses are regulated. Consistent with this idea, the model
demonstrates that under basal conditions, it is possible to
maintain the average concentration of cAMP across all com-
partments (total cAMP) at 1 mM, while in the caveolar
domain, the basal concentration is ;100 nM (see Fig. 2).
Although this level of cAMP is high enough to partially
activate PKA, it is still low enough to leave a concentration
range over which cAMP can signiﬁcantly modulate kinase
activity.
Effects of b-adrenergic receptor stimulation
We next evaluated the effect that b1AR stimulation has on
cAMP levels. As expected, the model predicts that b1AR
stimulation causes a concentration-dependent increase in
cAMP in all compartments of the cell (Fig. 2). Exposure to
the b1AR agonist isoproterenol (Iso) increases total cAMP
from basal (1 mM) to a maximal level ;2.1 mM with an
EC50 of ;7 nM. This is consistent with the 50–250%
increase over baseline, and EC50 of 10–80 nM observed
experimentally, when using traditional biochemical methods
to measure total cAMP in homogenized preparations
(7,9,48–51). The model also predicts that caveolar cAMP
reaches a similar concentration following maximal b1AR
stimulation, but because of the lower baseline (100 nM), the
overall change represents a .2000% increase.
Recently, we have used a ﬂuorescence energy transfer
(FRET)-based biosensor to measure changes in cAMP ac-
tivity in intact cardiac myocytes (47). This biosensor consists
of ﬂuorescently labeled type II PKA, and in adult ventricular
FIGURE 2 Effect of b1-adrenergic receptor activation on cAMP kinetics.
Effect of submaximally (3 nM) and maximally (100 nM) stimulating con-
centrations of isoproterenol on the time course of changes in cAMP concen-
tration. (A) Average concentration of cAMP in all compartments (total
cAMP, simulation). (B) Concentration of cAMP in the caveolar compart-
ment (caveolar cAMP, simulation). (C) Dependence of total and caveolar
cAMP (simulations) on concentration of isoproterenol used to stimulate
b1-adrenergic receptors.
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myocytes it is expressed in a striated pattern, suggesting that
it is associated with T tubules, just like endogenous type II
PKA (52,53). Caveolin-3, a marker for caveolae, is ex-
pressed in a similar striated pattern, in addition to being
found in the peripheral sarcolemma (54). Biochemical stud-
ies have also demonstrated that type II PKA is highly en-
riched in caveolar membrane fractions (34). Therefore, it
is assumed that this sensor responds to changes in cAMP
activity occurring in a caveolar compartment. Consistent
with this idea, we have previously demonstrated that this
sensor detects b1AR stimulated changes in cAMP activity
with a sensitivity that correlates directly with the b1AR
sensitivity of L-type Ca21 channels (47), which are located
in caveolae associated with T tubules (55). The properties of
this probe have also been well characterized in vitro (4). The
EC50 for cAMP activation is 300 nM, with a Hill coefﬁcient
of 1.4. Furthermore, activation by maximally effective con-
centrations of cAMP produces a FRET response of ;15%
(see Fig. 3 B). However, when expressed in ventricular
myocytes, this probe exhibits a smaller dynamic FRET
response (6–12%) following maximal agonist stimulation
(47,4). This can be explained if basal levels of cAMP are
sufﬁcient to have partially activated PKA, even before ex-
posure to agonist. Consistent with this idea, PKA-dependent
responses can be elicited from ventricular preparations by
inhibiting basal phosphatase activity (56).
If the in vitro properties of the probe described above hold
true in vivo, and if we assume that the averagemaximal FRET
response that can be elicited in adult ventricular myocytes is
9%, this then indicates that ;25% of the PKA-based probe
must be in an active state under basal conditions. This corre-
sponds to a basal level of cAMP that is close to that predicted
by the model to exist in the caveolar domain. Using the
relationship between Iso concentration and cAMP levels in
the caveolar compartment (Fig. 2 C), we then deﬁned the
expected relationship between Iso concentration and PKA
activation. According to this calculation, Iso increases PKA
activity from a basal level of 25% to maximal with an EC50 of
1.3 nM (Fig. 3 D). The sensitivity of this response is in good
agreement with the EC50 of 0.5 nM for Iso activation of the
PKA-based probe in intact ventricular myocytes (47). With
the relationship in Fig. 3 B, we can also use the model to
predict the FRET response of the PKA-based probe (Fig. 3C)
and compare this to experimentally determined PKA-FRET
responses (Fig. 3 A). The model’s predictions are in good
agreement with the experimental results. The one possible
exception is the difference in the time course with which
responses turn on and off. Although there may be more than
one explanation, it is most likely due to the slow exchange of
solutions used to add or remove drugs during the imaging
experiments (47). Consistent with this conclusion, the time
course of the responses predicted by the model are more in line
FIGURE 3 Simulation of b1-adrenergic responses. (A) In vivo activation of type II protein kinase A (PKA) by submaximally (0.3 nM) and maximally
(1 mM) stimulating concentrations of isoproterenol (experimental). Increase in PKA activity measured as change in FRET response (DR/R0) of PKA-based
biosensor expressed in an adult ventricular myocyte. Data fromWarrier et al. (47). (B) cAMP sensitivity of PKA-based biosensor in vitro. Data from Mongillo
et al. (4). (C) Predicted response of PKA-based biosensor in a ventricular myocyte exposed to submaximally and maximally stimulating concentrations of
isoproterenol (simulation). (D) Predicted isoproterenol sensitivity of PKA-based biosensor in vivo (simulation).
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with the timecourseof cAMP-dependent ion channel responses
observed when rapid solution changes are possible (13).
Effects of M2R activation in the presence of
maximal b-adrenergic stimulation
M2R activation is able to antagonize responses to agonists
that stimulate cAMP production. Although it is now gen-
erally accepted that such inhibitory effects are due to a de-
crease in cAMP production, this has not always been the case
(1). Many early studies measuring cAMP levels in homog-
enized tissue or whole cell lysates found that muscarinic
inhibitory responses do not correlate with changes in cAMP.
An explanation offered for this apparent paradox has been
that muscarinic inhibition of cAMP activity is localized
to speciﬁc subcellular compartments (10). Consistent with
this idea, the model predicts that M2R stimulation has only
modest effects on total cAMP levels (Fig. 4 C). However,
M2R activation signiﬁcantly reduces cAMP in the caveolar
compartment (Fig. 4 D). Furthermore, ACh inhibition of the
Iso response is reﬂected in the predicted FRET response
(Fig. 4 B), which correlates well with the PKA FRET re-
sponse observed experimentally (Fig. 4 A). Another predic-
tion of the model is that following the initial inhibitory effect
produced by ACh, there is a gradual decrease in inhibition
(‘‘escape’’), as observed experimentally (13). In the model,
this is due to M2Rs stimulating cAMP production in the ex-
tracaveolar compartment, which then spills over into the
caveolar compartment.
Effects of M2R activation in the presence of
submaximal b-adrenergic stimulation
Having demonstrated that the model can reproduce muscarinic
inhibition of b1AR-mediated cAMP production, we then
evaluated its ability to explain muscarinic stimulatory re-
sponses. Previous studies in ventricular myocytes have dem-
onstrated that muscarinic stimulatory effects are only observed
in the presence of submaximal concentrations of agonists such
as Iso (11–13). Consistent with this, the model predicts that
M2R activation would not produce a detectible rebound
stimulatory response in the presence of a maximally stimulat-
ing concentration of Iso (Fig. 4B). However, in the presence of
a concentration of Iso that is near the threshold for stimulating
PKA activity above basal levels, the model predicts that upon
termination of M2R activation, there should be a signiﬁcant
rebound stimulatory increase in cAMP concentration in the
caveolar compartment, which produces a rebound increase in
the predicted PKA FRET response (Fig. 5 B). This type of
response correlates with the PKA-FRET response observed
experimentally (Fig. 5A). Again, the slower time course of the
FRET response measured experimentally may be explained
FIGURE 4 Simulation of muscarinic inhibition of b1-adrenergic response. Effect of acetylcholine ((ACh) 10 mM) on the response to a maximally
stimulating concentration (200 nM) of isoproterenol (Iso). (A) In vivo PKA activity measured as change in FRET response (DR/R0) of PKA-based biosensor
expressed in an adult ventricular myocyte (experimental). Data from Warrier et al. (47). (B) Predicted response of PKA-based biosensor in a ventricular
myocyte (simulation). (C) Average concentration of cAMP in all compartments (total cAMP, simulation). (D) Concentration of cAMP in the caveolar
compartment (caveolar cAMP, simulation).
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by the time required to change solutions. The model also
predicts an inhibitory effect that goes below baseline during
exposure toACh, but the PKA-based probemay not be able to
detect changes in cAMP below basal levels (see Appendix II).
A more detailed examination of the source of cAMP
responsible for the rebound stimulatory response helps ex-
plain this complex behavior. This requires an appreciation of
what is happening not only in the caveolar compartment, but
also in adjacent compartments, especially the extracaveolar
compartment. In the model, M2Rs are located in both the
caveolar and extracaveolar compartments. However, the
caveolar compartment contains only AC5/6 activity, while
the extracaveolar compartment contains only AC4/7 activity.
In the presence of ACh, Gia inhibits AC5/6, rapidly reducing
cAMP in the caveolar compartment (Fig. 6, A and B).
However, ACh actually increases cAMP in the extracaveolar
compartment, where Gibg stimulates AC4/7 (Fig. 6 D). The
resulting concentration gradient produces a slow ﬂux of
cAMP between compartments (Fig. 6 C), but the inhibitory
effect of ACh on cAMP production within the caveolar
compartment dominates. Upon washout of ACh, AC5/6
inhibition quickly reverses, resulting in a rapid return of
cAMP production within the caveolar compartment. This
cAMP, together with ﬂux of cAMP from the extracaveolar
compartment, results in a caveolar concentration exceeding
that observed in the presence of Iso alone (before application
FIGURE 5 Simulation of muscarinic stimulatory response. Rebound
stimulatory effect observed following transient exposure to acetylcholine
((ACh) 10 mM) in the presence of a submaximally stimulating concentration
(0.1 nM) of isoproterenol (Iso). (A) In vivo PKA activity measured as change
in FRET response (DR/R0) of PKA-based biosensor expressed in an adult
ventricular myocyte (experimental). Data from Warrier et al. (47). (B) Pre-
dicted response of PKA-based biosensor in a ventricular myocyte (simula-
tion). (Dashed line) Predicted response if biosensor were able to detect
decreases in cAMP activity below basal levels (see Appendix II).
FIGURE 6 Kinetics of changes in cAMP activity associated with mus-
carinic stimulatory response. Changes in caveolar and extracaveolar cAMP
production and concentration caused by transient exposure to acetylcholine
((ACh) 10 mM) in the presence of a submaximally stimulating concentration
(0.1 nM) of isoproterenol (Iso) (simulations). (A) Concentration of cAMP
in the caveolar compartment. (B) Rate of cAMP concentration change in
the caveolar compartment due to the activity of AC5/6. (C) Rate of cAMP
concentration change in the caveolar compartment (Cav) due to the ﬂux from
the extracaveolar compartment (Ecav). (D) Concentration of cAMP in the
extracaveolar compartment. (E) Rate of cAMP concentration change in the
extracaveolar compartment due to the activity of AC4/7.
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of ACh). As the concentration of cAMP in the extracaveolar
compartment declines, so does the ﬂux of cAMP into the
caveolar compartment. The result is that caveolar cAMP
declines to its steady-state value. Based on these results, we
conclude that the diffusion of cAMP from the extracaveolar
compartment into the caveolar compartment is a viable
explanation for the rebound stimulatory responses observed
upon washout of ACh.
DISCUSSION
Computational models of cAMP signaling have recently
been used to investigate cardiac myocyte responses to b1AR
stimulation (23,22). This study expands this approach by incor-
porating the kinetics of processes involved in b1-adrenergic
as well as M2 muscarinic regulation of cAMP production and
integrating this with information on the subcellular distribu-
tion of the various components of these signaling pathways.
The model was tested by comparing cAMP responses pre-
dicted to occur in a caveolar compartment to previously pub-
lished measurements of changes in cAMP activity detected
by a FRET-based biosensor targeted to the corresponding
subcellular location of intact cardiac ventricular myocytes
(47). It was also tested by comparing total cAMP responses
(using the weighted average of the cAMP concentrations in
all three compartments) to previously published measure-
ments of changes in cAMP obtained using traditional bio-
chemical methods in ventricular tissue homogenates and/or
whole cell lysates. This new theoretical framework can ex-
plain both simple and complex behaviors of cardiac ven-
tricular myocytes evoked by both b1-adrenergic and M2
muscarinic signaling pathways.
The model provides a simple explanation for the ob-
servation that the total cellular cAMP level is high enough
that one would expect near maximal activation of PKA,
even under basal conditions. Measurements obtained using
homogenized cells or tissue reﬂect cAMP levels averaged
across the whole cell, not levels in microdomains that make
up only a small fraction of the total cell volume. Although
compartmentation of cAMP signaling is an obvious potential
explanation, that hypothesis is difﬁcult to evaluate experi-
mentally. The model predicts that bulk cytoplasmic cAMP
is comparable to previous estimates for the whole cell, but
cAMP in the caveolar compartment operates in a range
appropriate to modulate PKA activity. This obviates the
need to assume that the afﬁnity of PKA for cAMP is sig-
niﬁcantly lower in vivo than what has been measured in vitro
(22,57).
The model also can explain why muscarinic inhibition of
b-adrenergic functional responses has not always been found
to correlate directly with changes in cAMP levels (10). Be-
cause the discrepancies have been reported in studies where
cAMP levels were measured using whole cell or tissue pre-
parations, it has been proposed that signiﬁcant concentration
changes actually were occurring in microdomains where
PKA-dependent responses are regulated (10). In support of
this idea, the model predicts that M2R activation causes only
modest changes in cAMP concentration in the bulk cytoplas-
mic compartment (see Fig. 4 C), whereas there are signiﬁcant
changes in cAMP levels in the caveolar compartment (see
Fig. 4 D). Furthermore, the predicted effect of M2R activa-
tion on PKA responses in the caveolar compartment (Fig.
4 B) correlates well with experimental results demonstrating
that, in the presence of b1AR stimulation, M2R activation
reduces cAMP activity detected by the PKA-based cAMP
biosensor (Fig. 4 A).
We then used the model to determine whether compart-
mentation of cAMP can explain M2R-mediated delayed
stimulatory responses. In ventricular myocytes, this behavior
is due to Gi bg subunits stimulating AC4/7 activity (11).
However, this occurs at the same time that Gia is inhibiting
AC5/6. So why does the stimulatory effect produce a rebound
response upon termination of M2R activation? If AC4/7 and
AC5/6 are found in different plasmamembrane domains (21),
we hypothesized that a time-dependent ﬂux of cAMP from an
extracaveolar compartment to a caveolar compartment could
be responsible. The model demonstrates that this is a feasible
explanation. It is interesting to note that the muscarinic
stimulatory mechanism only affects functional responses
(e.g., ion channels) in the presence of submaximally stimu-
lating concentrations of Iso. The model actually predicts that
themuscarinic stimulatory response affects cAMP levels even
in the presence of maximally stimulating concentrations of
Iso, but because this rebound response is above the level that
maximally activates PKA, it is not expected to produce a
detectable functional response (see Fig. 4).
Limitations and predictions
Although descriptive information dealing with compartmen-
tation of cAMP signaling in cardiac myocytes is growing
rapidly, the availability of quantitative data is limited. Where
information does exist, it is not uncommon for there to be
some variability in estimates between different studies. Be-
cause of this, there may be more than one set of parameters
that produce the same behaviors we have described. In this
respect, this version of the model should be viewed as just
one potential conﬁguration, albeit one that exhibits proper-
ties consistent with a number of experimental observations.
Although a quantitative parameter analysis was beyond the
scope of this study, we did conduct a more qualitative type of
analysis of the importance of certain parameter in producing
speciﬁc responses.
Except where noted, the equations used in the model’s
different modules were taken from previously published
studies. This approach constrained many parameter values to
those that resulted in module output consistent with exper-
imental data. Less quantitative information was available
for assigning values to other parameters. This is particularly
true for the distribution of some signaling elements among
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subcellular compartments and the ﬂux rates for cAMP
between compartments. These were the parameters that
turned out to have the greatest inﬂuence on the behaviors that
were the focus of this study.
Experimental data also do not provide a consistent view
on the location of b1ARs. Some studies have suggested that
the bulk of the b1AR population exists in an extracaveolar
domain (34), whereas others have concluded that the same
receptor is found predominantly in a caveolar domain (58).
The present version of the model assumes that b1ARs are
found in both of these compartments. The validity of this
assumption might be questioned, but it was necessary in
order for b1AR stimulation to activate both AC5/6 and
AC4/7. Stimulation of AC5/6 was necessary to produce an
increase in cAMP that could then be inhibited by M2R
activation. Stimulation of AC4/7 was necessary to see ACh-
induced rebound stimulation of cAMP production. Because
these different AC isoforms are found in different membrane
domains (21,27), the simplest way to model these behaviors
was to include b1ARs in those domains as well. This illus-
trates how the model can be used to evaluate the functional
signiﬁcance of biochemical data describing the location of
speciﬁc elements or even differentiating between possibil-
ities. Using this approach, our results provide support for the
idea that b1ARs actually exist in caveolar as well as extra-
caveolar domains.
One aspect of the model that is absolutely critical for
producing the ACh-induced rebound stimulatory response is
the placement of AC5/6 inside and AC4/7 outside of the
caveolar compartment. Although this behavior is not lost if
the distribution ofAC isoforms is less strict, segregation of the
majority of AC activity is important. This conclusion is con-
sistentwith biochemical studies that have looked at the distribu-
tion of AC activity in different membrane fractions (27,21).
It was not necessary to include more than one type of PDE
activity to obtain the basic properties of this model. What
was important was the ratio of PDE to AC activity in each
compartment. Furthermore, it was critical to have much
higher total PDE activity in the caveolar compartment than
either of the other two compartments. This was necessary to
maintain a low concentration of cAMP in the caveolar
domain under basal conditions, while still allowing cAMP
levels in the other compartments (and thus total cAMP)
to remain high. Similarly, the transient rebound response
observed following washout of ACh can be reproduced by
including a single type of PDE activity in the extracaveolar
domain that is much lower than that in the caveolar com-
partment. So one might question why we included three
different types of PDE activity in the model. The primary
reason is that there have been numerous studies demonstrat-
ing the functional importance of PDE2, PDE3, and PDE4
activity in regulating cAMP-dependent responses in adult
cardiac myocytes (59,60), and we wanted the model to
reﬂect what is known about PDE activity in these cells.
Unfortunately, there is little information available on how
the different PDE isoforms are distributed. Biochemical
studies have found evidence for all three isoforms in both
soluble and particulate fractions of cell homogenates, and
while the PDE activity in particulate fractions may be
membrane associated, there is little or no information on how
much of that might be caveolar and/or extracaveolar.
Fortunately, the behaviors described by this model did not
depend critically on exactly which PDE isoforms were
present in each compartment. Another reason to include
multiple PDE isoforms in the model is that each can be
regulated in unique ways that may be necessary to explain
other types of responses. For example, PDE4 can be acti-
vated by PKA (61). Previous work has suggested that this is
involved in a feedback mechanism that can modulate the
magnitude of cAMP responses detected by exogenously ex-
pressed cyclic nucleotide gated (CNG) ion channels (62).
However, the subcellular location where this positive feed-
back activation of PDE4 may be occurring is not clear.
Although it is obvious that CNG channels detect responses
near the plasma membrane, they are expressed primarily in
noncaveolar lipid rafts (63), and how this may relate to
compartments included in this model is not known.
The parameters about which we have the least information
relate to the ﬂux of cAMP within a cell. Movement of cAMP
between compartments is often thought of as being limited
by functional barriers associated with PDE activity (7). In
this model, the role of PDE activity in regulating the ﬂux
between compartments is actually through its contribution to
the concentration of cAMP in each compartment, and there-
fore the concentration gradient driving cAMP movement
between compartments. Flux of cAMP between compart-
ments is also a function of physical factors affecting dif-
fusion of cAMP down its concentration gradient. If it is
assumed that there are no physical barriers and cAMP can
move between compartments at rates that approximate free
diffusion, all of the behaviors attributed to compartmentation
by this model are lost. This includes the gradient of cAMP
between the caveolar and extracaveolar domain under basal
conditions, as well as the ACh-induced rebound stimulatory
response. The complex structure of cardiac ventricular
myocytes has been shown to restrict access to submembrane
regions and is likely to be an important factor inﬂuencing
cAMP diffusion (64), but the actual nature of the barriers
between compartments proposed in the model is not known.
The ﬂux rates predicted by this model indicate that cAMP
movement is far slower than free diffusion. Validation of
these values awaits development of an approach to exper-
imentally determine cAMP ﬂux rates between speciﬁc micro-
domains in intact myocytes. It is noteworthy that Rich et al.
(65) also found evidence for extremely slow exchange of
cAMP among compartments in HEK 293 cells, indicating
that limited diffusion between microdomains is not unique to
cardiac myocytes. More recently, Saucerman et al. (66) have
demonstrated that limited diffusion of cAMP also occurs at
the macroscopic level in neonatal ventricular myocytes.
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Future directions
This version of the model only contains b1ARs, whereas
most cardiac preparations express both b1 and b2ARs.
However, b1ARs make up ;80% of the total bAR popula-
tion, and in normal hearts b2ARs do not contribute sig-
niﬁcantly to the functional responses of ventricular myocytes
to nonselective agonists such as Iso. Furthermore, the model’s
predictions were validated by comparison to responses
obtained from guinea pig ventricular myocytes, which unlike
most cardiac preparations, do not express functional b2ARs
(67). In cardiac preparations where they do exist, b2ARs may
play a more important role in regulating cardiac function
under conditions such as heart failure. Interestingly, selective
activation of b2ARs produces compartmentalized cAMP-
dependent responses. Future incorporation of b2ARs into the
model may provide a useful means of evaluating the potential
mechanism(s) responsible for that form of compartmenta-
tion. Another key future direction for the model is inclusion
of signaling mechanisms downstream of cAMP.
CONCLUSIONS
This work supports the idea that compartmentation of cAMP
signaling plays a critical role in shaping cAMP-dependent
effects under basal conditions, as well as in response to
b1AR and M2R activation. This includes both the inhibitory
and stimulatory responses associated with M2R activation.
APPENDIX I
All parameters used in the model and their respective references are listed in
Tables 2–8.
TABLE 2 Isoproterenol/b1 adrenergic receptor/Gs module
Parameter Value Units Description Reference
Rb1TotalCav 0.633 mM Concentration of b1R
in Cav compartment
(30)
Rb1TotalEcav 1.267 mM Concentration of b1R
in Ecav compartment
(30)
KH 0.035 mM High afﬁnity binding constant
(between ligand and receptor)
(78,79)
KL 0.386 mM Low afﬁnity binding constant
(between ligand and receptor)
(79,78)
KC 8.809 mM Afﬁnity binding constant (between
free receptor and G-protein)
(80,22)
TABLE 3 Acetylcholine/M2 muscarinic receptor/Gi module
Parameter Value Units Description Reference
RM2TotalCav 0.506 mM Concentration of M2R
in Cav compartment
(81)
RM2TotalEcav 0.506 mM Concentration of M2R
in Ecav compartment
(81)
KH 0.16 mM High afﬁnity binding constant
(between ligand and receptor)
(82)
KL 11 mM Low afﬁnity binding constant
(between ligand and receptor)
(82)
KC 30 mM Afﬁnity binding constant (between
free receptor and G-protein)
(80,22)
TABLE 4 G-protein activation module
Parameter Value Units Description Reference
GsTotalCav 10 mM Concentration of Gs-protein
in Cav compartment
(30,34)
GsTotalEcav 10 mM Concentration of Gs-protein
in Ecav compartment
(83,34)
GiTotalCav 20 mM Concentration of Gi-protein
in Cav compartment
(33,32,34)
GiTotalEcav 1 mM Concentration of Gi-protein
in Ecav compartment
(34,33,32)
kact1Gi 0.05 s
1 Activation rate constant
for LRGi complexes
(35,22)
kact2Gi 2.5 s
1 Activation rate constant
for RGi complexes
(35,22)
kact1Gs 0.1 s
1 Activation rate constant
for LRGs complexes
(35,22)
kact2Gs 5 s
1 Activation rate constant
for RGs complexes
(35,22)
khydrGi 0.8 s
1 Hydrolization rate constant
of Gia-GTP
(35,22)
kreasGi 1.21 3 10
3s1 mM1kreasGi, reassociation rate
constant of Gia-GDP and Gbg
(35,22)
khydrGs 0.8 s
1 Hydrolization rate
constant of Gsa-GTP
(35,22)
kreasGs 1.21 3 10
3s1 mM1kreasGi, reassociation rate
constant of Gsa-GDP and Gbg
(35,22)
TABLE 5 Adenylyl cyclase 5/6 module
Parameter Value Units Description Reference
AC5/6 3.379 mM Concentration of
AC5/6
(30)
ATP 5 3 103 mM Concentration of
ATP (constant)
(28)
KmATP 315 mM AC5/6 Km for
ATP
(84)
AF5/6 500
mgpurified protein
mgmembrane protein
Ampliﬁcation
factor for
AC5/6
–
MWAC5/6 130 KDa Molecular weight
of AC5/6
–
TABLE 6 Adenylyl cyclase 4/7
Parameter Value Units Description Reference
AC4/7-Ecav 0.200 mM Concentration
of Ecav AC4/7
(30,45,44)
AC4/7-Cyt 0.379 3 10
3 mM Concentration
of Cyt AC4/7
(30,45,44)
ATP 5 3 103 mM Concentration
of ATP
(constant)
(28)
KmATP 315 mM AC4/7 Km for
ATP
(84)
AF4/7 130
mgpurified protein
mgmembrane protein
Ampliﬁcation
factor for
AC4/7
–
MWAC4/7 130 KDa Molecular weight
of AC4/7
–
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APPENDIX II: EFFECTS OF M2R ACTIVATION IN
THE ABSENCE OF b-ADRENERGIC STIMULATION
In ventricular myocytes, M2R activation alone produces no functional
response as a consequence of changes in cAMP activity (1). This does not
necessarily mean that exposure to a muscarinic agonist such as acetylcholine
(ACh) does not affect cAMP concentrations in caveolar domains. If basal
levels of cAMP are sufﬁcient to at least partially activate PKA, the absence
of its inﬂuence on functional responses can be explained by basal phos-
phatase activity (56). Consistent with this idea, the model actually predicts
that exposure to ACh alone does cause a decrease in caveolar cAMP levels
(Fig. 7 D), as well as a decrease in the predicted FRET-response (Fig. 7 B).
However, ACh has no effect on the FRET-response of the PKA-based bio-
sensor in intact cardiac ventricular myocytes (Fig. 7 A). This apparent
discrepancy is most likely due to the inability of the sensor to detect
decreases in basal cAMP activity.
In cells expressing the PKA-based biosensor, acute exposure to an
agonist that stimulates cAMP production causes a decrease in FRET (in-
crease in the FRET response) that is readily reversible (Figs. 3–5). This can
be explained by the fact that cAMP binding to RII-CFP does not necessarily
cause complete dissociation of Cat-YFP in the absence of substrate (47).
Therefore, these labeled subunits can readily reassociate when cAMP levels
TABLE 7 Phosphodiesterase modules
Parameter Value Units Description Reference
KmPDE2 50 mM PDE2 Km for cAMP (72, 85)
KmPDE3 0.08 mM PDE3 Km for cAMP (76)
KmPDE4 2.2 mM PDE4 Km for cAMP (86)
kPDE2 20 s
1 Rate constant for PDE2 (72)
kPDE3 1.25 s
1 Rate constant for PDE3 (72)
kPDE4 2.5 s
1 Rate constant for PDE4 (72)
PDE2Cav 4.5 mM PDE2 concentration
in Cav compartment
(87,85)
PDE2Ecav 0.02 mM PDE2 concentration
in Ecav compartment
(87,85)
PDE2Cyt 5 3 10
3 mM PDE2 concentration
in Cyt compartment
(85)
PDE3Cav 5.6 mM PDE3 concentration
in Cav compartment
(76,23,85)
PDE3Cyt 7.5 3 10
3 mM PDE3 concentration
in Cyt compartment
(85,76,23)
PDE4Cav 2.0 mM PDE4 concentration
in Cav compartment
(85,88,23)
PDE4Ecav 0.16 mM PDE4 concentration
in Ecav compartment
(85,88,23)
PDE4Cyt 5 3 10
3 mM PDE4 concentration in Cyt
compartment
(85,88,23)
FIGURE 7 SimulationofM2muscarinic responses in the absenceofb1-adrenergic stimulation. (A) Effect of amaximally stimulating concentrationof acetylcholine
on the activity of the PKA-based biosensor expressed in an adult ventricular myocyte (experimental). Data fromWarrier et al. (47). (B) Predicted response of PKA-
basedbiosensor in a ventricularmyocyte exposed to amaximally stimulating concentrationof acetylcholine (simulation). (Dashed line) Predicted response if biosensor
were able to detect decreases in cAMP activity below basal levels. (C) Change in total cAMP concentration in response to a maximally stimulating concentration of
acetylcholine (simulation). (D) Change in caveolar cAMP concentration in response to a maximally stimulating concentration of acetylcholine (simulation).
TABLE 8 cAMP ﬂux modules
Parameter Value Units Description Reference
JCav/Ecav 7.5 3 10
15 Liters 3 s1 Flux rate between
Cav and Ecav
compartments
(65)
JCav/Cyt 7.5 3 10
14 Liters 3 s1 Flux rate between
Cav and Cyt
compartments
(65)
JEcav/Cyt 1.5 3 10
17 Liters 3 s1 Flux rate between
Ecav and Cyt
compartments
(65)
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decrease, resulting in an increase in FRET (decrease in FRET response).
However, under basal conditions, it is more likely that the regulatory and
catalytic subunits of activated PKA do completely dissociate. In this
situation, there is a greater chance that ﬂuorescently labeled subunits
reassociate with unlabeled endogenous counterparts, in which case there will
be no change in FRET, or the FRET response. Therefore, the absence of a
decrease in the FRET response upon exposure to ACh under basal
conditions does not necessarily mean that cAMP levels have not decreased.
The model also predicts that exposure to high concentrations of ACh
actually causes a slight increase in total cAMP (Fig. 7 C). Although this type
of response might seem counterintuitive, it is consistent with what has been
observed experimentally when measuring cAMP responses with biochem-
ical methods in ventricular tissue homogenates (68). The model can explain
such effects as being due to the ability of M2R activation to stimulate cAMP
production in the extracaveolar compartment.
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